Background: Sual-e-Yabis (dry cough) is a common respiratory ailment described in classical Unani texts as a condition primarily of Yabusiyat (dryness) affecting the respiratory tract. Sharbat-e-Ejaz is a compound Unani formulation included in the Unani Pharmacopoeia of India (UPI) with documented anti-tussive and mucolytic properties. Objective: To clinically validate the efficacy and safety of Sharbat-e-Ejaz in patients with Sual-e-Yabis through a multi-centre open-label clinical trial. Methods: A total of 128 patients (Male: 88, Female: 40) with confirmed diagnosis of Sual-e-Yabis were enrolled from four CCRUM research institutes. The formulation was administered orally for four weeks with assessments at baseline, 2nd week (1st follow-up) and 4th week (end of treatment). Primary outcome was assessed using the Visual Analogue Scale (VAS). Laboratory investigations including haematological and biochemical parameters were performed to assess safety. Results: Mean VAS score significantly decreased from 7.91 ± 1.35 at baseline to 2.69 ± 1.18 at end of treatment, reflecting a 65.9% reduction (p < 0.001). No clinically significant adverse changes were observed in laboratory parameters. Conclusion: Sharbat-e-Ejaz demonstrated significant clinical efficacy and acceptable safety profile in the management of Sual-e-Yabis, supporting its validation as a standard Unani therapeutic formulation.